Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III

This article was originally published on Nasdaq

Ionis Pharmaceuticals, Inc. IONS announced top-line data from the phase IIb SOLANO study, which evaluated its PCSK9 antisense medicine, ION449 (AZD8233), for the treatment of patients with hypercholesterolemia.

Responses